MARATTO

other · Figshare

Proximity-enhanced co-immobilized enzyme cascade for efficient bioconversion of nicotine to 3-succinoylpyridine

2026Open accessFayoum University

Abstract

Abstract Tobacco waste, rich in nicotine, is both an environmental burden and a potential feedstock for high-value chemicals. Here, we developed a proximity-enhanced co-immobilized multi-enzyme cascade that efficiently converts the nicotine into a pharmaceutical intermediate 3-succinoylpyridine (SP). The cascade system comprises the nicotine oxidoreductase NicA2 V321 (NicAm), pseudooxynicotine amine oxidase (Pnao), and 3-succinoylsemialdehyde-pyridine dehydrogenase (Sapd) for sequential nicotine conversion, coupled with an aldehyde–ketone reductase (AKR) module for in situ NADP+ regeneration. To improve nicotine-to-SP conversion and facilitate multi-enzyme recycling, a SpyCatcher/SpyTag self-assembled cofactor regeneration enzyme scaffold was adopted, in conjunction with AviTag–BirA-mediated biotinylation for cascade enzyme site-specific co-immobilization on streptavidin-coated supports. This proximity-enhanced design promoted efficient cofactor cycling and boosted the nicotine-to-SP conversion to approximately 63%, much higher than the 42.7% achieved by free enzymes. The co-immobilized system also showed improved pH and thermal stability, retaining over 60% of its initial activity after eight reuse cycles. This modular biocatalytic strategy provides a green and promising route for the valorization of nicotine-rich tobacco waste.

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.6084/m9.figshare.c.8475888.v1

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.